GSK Pharma India Share Price Performance and Trends

GSK Pharma India has consistently delivered strong financial performance, with its share price reflecting the company's growth trajectory. The share price has shown a steady increase over the years, making it an attractive investment opportunity for many.

In the past five years, GSK Pharma India's share price has risen by over 50%, outperforming the market average. This significant growth can be attributed to the company's strong brand portfolio and robust distribution network.

GSK Pharma India's diversified product portfolio, which includes vaccines, respiratory, and consumer healthcare products, has contributed to its stable revenue streams. This diversification has helped the company navigate market fluctuations and maintain its market position.

The company's focus on innovation and research and development has also contributed to its growth, with a strong pipeline of new products in the pipeline.

For more insights, see: Gsk Pharma Share Price

Financial Information for GSK Pharma India Share Price is readily available in various formats. You can find detailed financial statements, including balance sheets, profit and loss statements, and cash flow statements, which are crucial for making informed investment decisions.

To get a clear picture of GSK Pharma's financial health, you can look at their quarterly results, half-yearly results, nine months results, and yearly results. This information can be found in the Financial Statements section of their reports.

GSK Pharma's income statement, also known as the profit and loss statement, provides a breakdown of their revenue and expenses over a specific period. You can also find their balance sheet, which shows their assets, liabilities, and equity at a particular point in time.

If you're interested in technical analysis, you can look at GSK Pharma's chart, which can help you identify trends and patterns in their share price. Additionally, you can find pivot levels and average true range (ATR) analysis, which can be useful for making buy or sell decisions.

Here is a summary of the key financial information you can find for GSK Pharma India share price:

This information can be found in the GSK Pharma Financials section of their reports.

The performance of GlaxoSmithKline Pharmaceuticals Ltd is quite impressive. The company's sector price-to-earnings ratio (P/E) is 37.05, which is a significant indicator of its growth prospects.

GlaxoSmithKline Pharmaceuticals Ltd has a sector price-to-book ratio (P/B) of 5.85, which suggests that the company's stock is undervalued compared to its peers. The sector dividend yield is a mere 0.58%, indicating that the company may not be distributing a significant portion of its profits to shareholders.

In comparison to its peers, GlaxoSmithKline Pharmaceuticals Ltd has a higher P/E ratio of 50.54, indicating that investors expect the company to grow at a faster rate than its competitors. The company's P/B ratio is also higher at 24.03, suggesting that the company is more expensive than its peers. The dividend yield of 1.95% is also higher than its peers, indicating that the company is distributing a significant portion of its profits to shareholders.

Here's a comparison of the key metrics of GlaxoSmithKline Pharmaceuticals Ltd and its peers:

Overall, GlaxoSmithKline Pharmaceuticals Ltd's performance is a mixed bag, with some positive indicators and some negative ones.

GLAXO Sentiment Analysis is a key indicator of the company's performance. The company has reported flat growth overall, with a negative volume growth of 1% in recent times.

Supply chain disruptions have been a major concern for the company. A fire incident at a contract manufacturing organization led to supply shortages.

GSK Pharma share price insights reveal some interesting facts. The company has no debt since the last 5 years, which is a significant advantage.

Quarterly topline performance has been a concern, with a QoQ revenue decline of 16.37% in the last quarter. This is the lowest decline in the last 3 years.

A buy signal has been triggered, with a weekly stochastic crossover appearing on week ending October 10, 2025. This signal has been accurate in the past, with an average price gain of 7.26% within 7 weeks.

Employee and interest expenses have been kept under control, with less than 1% of operating revenues spent on interest expenses and 15.46% on employee cost in the year ending March 31, 2025.

The current share price of Rs 2,767.40 is a 0.24% increase from the previous close of Rs 2,761.00.

Here's an interesting read: Rs Software India Ltd Share Price

In the latest annual report, GlaxoSmithKline Pharmaceuticals Ltd has received a "Pro" buy recommendation, indicating a strong potential for growth.

The company's upside potential is significant, with a notable 1Y Forward EPS Growth rate.

GlaxoSmithKline Pharmaceuticals Ltd's stock is showing promising signs, with a buy recommendation from analysts.

Here's a brief overview of the companies mentioned in the annual report:

The share price of GSK Pharma India has been steadily increasing over the years. As of the latest data available, the share price of GSK Pharma India is around ₹1,450 per share.

GSK Pharma India's market capitalization is a significant indicator of its financial health. With a market capitalization of over ₹50,000 crores, the company is one of the largest pharmaceutical companies in India.

Investors can hold shares in GSK Pharma India through various routes, including demat accounts and stock exchange platforms.

Recommended read: Glaxosmithkline Plc Stock

The share price of a company is the current market value of one share of its stock.

It's affected by factors such as supply and demand, economic conditions, and company performance.

A company's share price can fluctuate rapidly in response to news and events.

For example, a sudden increase in demand for a company's product can drive up its share price.

The share price is an important indicator of a company's financial health and performance.

It's also a key consideration for investors making buying or selling decisions.

In general, a higher share price indicates a more valuable company.

However, a higher share price also means investors may need to pay more to buy a share.

Some companies have a fixed share price due to certain market conditions or regulations.

This is less common than a fluctuating share price.

Investors should monitor the share price regularly to make informed decisions.

They can also use tools like charts and graphs to track changes over time.

The shareholding pattern of GSK Pharma is a crucial aspect to consider when evaluating its share price. GSK Pharma is primarily owned by promoters, who hold a significant 75% stake as of September 2025.

The promoters' shareholding has remained constant at 75% across the past four quarters. The percentage of shares held by the promoters has not changed quarter-over-quarter.

In terms of the number of shares, the promoters hold 12,70,54,524 shares as of September 2025. This represents 75% of the total shares outstanding.

The shareholding pattern of GSK Pharma also includes a small percentage of shares held by foreign institutional investors (FII), who hold 5% of the shares as of September 2025. This is a slight increase from the previous quarter, where FII held 4.89% of the shares.

Here's a breakdown of the shareholding pattern of GSK Pharma as of September 2025:

GLAXO's financial performance is a crucial aspect to consider when evaluating GSK Pharma India's share price. The company's revenue, earnings, and cash flow are all important indicators of its financial health.

According to the table, GLAXO's PE Ratio is 50.54, which is significantly higher than its PB Ratio of 24.03. This suggests that investors are willing to pay a premium for the company's stock.

In comparison, Sun Pharmaceutical Industries Ltd has a PE Ratio of 36.68, which is lower than GLAXO's. This could indicate that investors have lower expectations for Sun Pharmaceutical's future growth.

Here's a brief comparison of the PE Ratios of the mentioned companies:

The Dividend Yield for GLAXO is 1.95%, which is relatively high compared to other companies in the industry. This could be an attractive feature for investors looking for regular income.

Forecasts are a crucial aspect of business planning, and Glaxo's forecasts are no exception. Glaxo Forecasts predict a significant increase in revenue, which is expected to reach ₹ Thousand cr.

One of the key areas of focus is earnings, which are also expected to see a substantial rise. The exact figure is not specified, but it's clear that Glaxo is aiming high.

Cash flow is another important metric that Glaxo is keeping an eye on, with a forecasted increase in this area as well. The ratio of cash flow to other financial metrics is also expected to improve.

Overall, Glaxo's forecasts are looking positive, with a focus on growth and improvement across the board.

If this caught your attention, see: Stock and Flow

In the world of pharmaceuticals, GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) is a well-established player. Its peer comparison with other companies in the industry is a crucial aspect of understanding its performance.

GSK Pharma's board meetings and AGMs are well-documented, with key meetings taking place on August 1, 2025, June 27, 2025, and May 13, 2025. These meetings are announced in advance, with the latest announcement on July 4, 2025.

The company's dividend history is also impressive, with a final dividend of 420% declared on May 13, 2025, and an ex-dividend date of May 30, 2025. This dividend is in addition to the interim dividend of 120% declared on October 24, 2024.

GSK Pharma's peer comparison is also notable in terms of its technical performance. According to the data, the company's PE ratio is 50.54, PB ratio is 24.03, and dividend yield is 1.95%.

Here's a comparison of GSK Pharma with its peers:

This comparison gives us an idea of how GSK Pharma's technical performance stacks up against its peers.

GSK Pharma India is a subsidiary of GlaxoSmithKline, a global pharmaceutical company.

GSK Pharma India was established in 1924 in India, making it one of the oldest pharmaceutical companies in the country.

The company's headquarters is located in Mumbai, Maharashtra.

GSK Pharma India has a strong presence in the Indian pharmaceutical market, with a wide range of products and services.

GSK Pharma India's product portfolio includes vaccines, respiratory, and consumer healthcare products.

The company's focus on research and development has led to the launch of several innovative products in the Indian market.

GSK Pharma India has a robust distribution network, with a presence in over 20,000 retail outlets across the country.

The company has a strong commitment to improving healthcare outcomes in India, through its various initiatives and programs.